![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sorrento Therapeutics Releases Positive Results from Asthma Trial
Sorrento Therapeutics Releases Positive Results from Asthma Trial
May 20, 2016
Sorrento Therapeutics has released positive data from a combination Phase 2/Phase 3 clinical study in China evaluating its STI-004 biosimilar of Genentech’s Xolair in patients suffering from allergic asthma.
The candidate reached its primary endpoint of reducing asthma exacerbations, with 21 percent of patients taking STI-004 experiencing asthma exacerbation versus 55 percent in the placebo group.
Upcoming Events
-
21Oct